Incorporating MRD Testing into Standard Practice: Are We There Yet?
Release Date: August 27, 2018
Expiration Date: August 27, 2019
Expected time to complete this activity as designed: 30 minutes
There are no fees for participating in or receiving credit for this online activity.
With modern therapy, many patients with multiple myeloma are achieving a complete response, but some will still experience a relapse after treatment, in part because of the presence of minimal residual disease (MRD). Molecular remission of MRD is a goal of therapy because it may potentially improve patient outcomes, but it is important to balance the need for achieving MRD negativity with the short- and long-term side effects of therapy. Several different methods are available to monitor MRD. In this activity, Dr. Faith Davies discusses the role of MRD in patients with multiple myeloma and compares current methodologies used to measure MRD. She also outlines the clinical applicability of incorporating MRD testing into routine clinical practice.
This activity is designed for multidisciplinary healthcare providers in the community setting, including hematologists, oncologists, pharmacists and other allied healthcare professionals who provide care to patients with multiple myeloma.
Upon completion of this educational activity, participants should be able to:
- Describe the importance of monitoring minimal residual disease (MRD) in patients with multiple myeloma
- Compare and contrast current methodologies used to measure MRD
- Outline the clinical applicability and goal of MRD testing in clinical practice
Incorporating MRD Testing into Standard Practice: Are We There Yet? – Faith Davies, MD, MBBCh, MRCP, FRCPath
Instructions for Participation and Credit
This activity is eligible for credit through August 27, 2019. After this date, this activity will expire and no further credit will be awarded.
- Read the target audience, learning objectives, and faculty disclosures.
- You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
- Complete the educational content as designed.
- Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
- Complete the activity evaluation survey to provide feedback and information useful for future programming.
- Certificates for CME credit may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.
Faith Davies, MD, MBBCh, MRCP, FRCPath
Professor of Medicine
Medical Director, Myeloma Institute
University of Arkansas for Medical Sciences
Little Rock, Arkansas
Dr. Faith Davies earned her medical degree from the University of Wales College of Medicine and completed her general medical training and hematology specialty training in the United Kingdom. She then held positions with the Institute of Cancer Research and the Royal Marsden Hospital, both in London, prior to moving to the USA. Dr. Davies is a Professor of Medicine and Deputy Director of the Myeloma Institute at the University of Arkansas for Medical Sciences in Little Rock, Arkansas.
Dr. Davies is a member of the American Society of Hematology, the American Association for Cancer Research, the Royal College of Physicians (UK), and the Royal College of Pathologists (UK). She is widely published in The New England Journal of Medicine, Blood, Journal of Clinical Oncology, Leukemia, and The Lancet Oncology, among others. Her clinical research focuses on the treatment of multiple myeloma, particularly the investigation of new drugs and genetic technologies to improve patient outcomes. Her laboratory work is aimed at identifying biologically based therapeutic targets in myeloma that are amenable to small-molecule interventions and translating those laboratory findings into the clinical arena to provide individualized treatment.
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 0.5 contact hours of Continuing Education Credit. Universal Activity Number: 827-0000-18-023-H01-P. Knowledge-based CPE activity.
In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.
Dr. Faith Davies has received honoraria as a consultant from AbbVie Inc., Amgen Inc., Bristol-Myers Squibb Company, Celgene Corporation, Janssen Pharmaceuticals, Inc., and Takeda Oncology.
Planning Committee Disclosures
The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Kristin Burke, Project Manager, Keith D’Oria, Medical Writer, and Joan Meyer, RN, MHA, Executive Director, have no relevant financial relationships.
Peer Reviewer Disclosure
In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.
If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at email@example.com
Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Amgen, Bristol-Myers Squibb, Celgene Corporation, and Takeda Oncology
©2018 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.